Research article
Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies
Sandra Dial, Khalid Alrasadi, Chantal Manoukian, Allen Huang and Dick Menzies
CMAJ July 06, 2004 171 (1) 33-38; DOI: https://doi.org/10.1503/cmaj.1040876
Sandra Dial
Khalid Alrasadi
Chantal Manoukian
Allen Huang
![Loading Loading](https://www.cmaj.ca/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data supplements
Early Release
Files in this Data Supplement:
Related Articles
- (2004). Highlights of this issue. CMAJ, 171(1), 9. Accessed August 18, 2024. Retrieved from http://www.cmaj.ca/content/171/1/9.
- Eggertson, L., & Sibbald, B. (2004). Hospitals battling outbreaks of C. difficile . CMAJ, 171(1), 19-21. Accessed August 18, 2024. https://doi.org/10.1503/cmaj.1040979.
- Valiquette, L., Low, D. E., Pépin, J., & McGeer, A. (2004). Clostridium difficile infection in hospitals: a brewing storm. CMAJ, 171(1), 27-29. Accessed August 18, 2024. https://doi.org/10.1503/cmaj.1040957.
- Louie, T. J., & Meddings, J. (2004). Clostridium difficile infection in hospitals: risk factors and responses. CMAJ, 171(1), 45-46. Accessed August 18, 2024. https://doi.org/10.1503/cmaj.1040966.
- Loo, V. G., Libman, M. D., Miller, M. A., Bourgault, A., Frenette, C. H., Kelly, M., Michaud, S., Nguyen, T., Poirier, L., Vibien, A., Horn, R., Laflamme, P. J., & René, P. (2004). Clostridium difficile: a formidable foe. CMAJ, 171(1), 47-48. Accessed August 18, 2024. https://doi.org/10.1503/cmaj.1040836.
- Poutanen, S. M., & Simor, A. E. (2004). Clostridium difficile-associated diarrhea in adults. CMAJ, 171(1), 51-58. Accessed August 18, 2024. https://doi.org/10.1503/cmaj.1031189.
In this issue
CMAJ
Vol. 171, Issue 1
6 Jul 2004
Article tools
Respond to this article
Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies
Sandra Dial, Khalid Alrasadi, Chantal Manoukian, Allen Huang, Dick Menzies
CMAJ Jul 2004, 171 (1) 33-38; DOI: 10.1503/cmaj.1040876
Jump to section
Related Articles
Cited By...
- Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study
- Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study
- Development and Validation of a web-based Postoperative Clostridioides difficile infection risk prediction model
- Impact of a pharmacist-driven protocol to decrease proton pump inhibitor use in non-intensive care hospitalized adults
- An assessment of human gastric fluid composition as a function of PPI usage
- Statin use and the risk of Clostridium difficile in academic medical centres
- Prophylaxis rates for venous thromboembolism and gastrointestinal bleeding in general medical patients: too low or too high?
- Fourteen-Genome Comparison Identifies DNA Markers for Severe-Disease-Associated Strains of Clostridium difficile
- Is double coverage of gram-negative organisms necessary?
- Current and future treatment modalities for Clostridium difficile-associated disease
- Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease
- Clostridium difficile-Associated Disease: Diagnosis, Prevention, Treatment, and Nursing Care
- Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis
- Stress ulcer prophylaxis in hospitalized patients not in intensive care units
- Hypervirulent strains of Clostridium difficile
- In Vitro Killing of Nosocomial Pathogens by Acid and Acidified Nitrite
- Suppression of Gastric Acid Production by Proton Pump Inhibitor Treatment Facilitates Colonization of the Large Intestine by Vancomycin-Resistant Enterococcus spp. and Klebsiella pneumoniae in Clindamycin-Treated Mice
- Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy.
- Proton pump inhibitors and the risk of Clostridium difficile-associated disease: further evidence from the community.
- Molecular Analysis of Clostridium difficile PCR Ribotype 027 Isolates from Eastern and Western Canada
- Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec
- How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?
- Audit is important part of drug safety and regulation
- Contemporary strategies for the prevention of stress-related mucosal bleeding
- Clostridium difficile colitis: A marker for ischemic colitis?
- Clostridium difficile colitis: A marker for ischemic colitis?
- Clostridium difficile infection in hospitals: a brewing storm
- Clostridium difficile: a formidable foe
- First, the bad news...
- Clostridium difficile infection in hospitals: risk factors and responses
- D'abord, la mauvaise nouvelle ...